Literature DB >> 29305627

Antagonism at the NR2B subunit of NMDA receptors induces increased connectivity of the prefrontal and subcortical regions regulating reward behavior.

Natalia Gass1, Robert Becker2, Markus Sack2, Adam J Schwarz3,4, Jonathan Reinwald2, Alejandro Cosa-Linan5, Lei Zheng2, Christian Clemm von Hohenberg2, Dragos Inta6, Andreas Meyer-Lindenberg6, Wolfgang Weber-Fahr2, Peter Gass6, Alexander Sartorius2,6.   

Abstract

RATIONALE: Evidence indicates that ketamine's rapid antidepressant efficacy likely results from its antagonism of NR2B-subunit-containing NMDA receptors (NMDAR). Since ketamine equally blocks NR2A- and NR2B-containing NMDAR, and has affinity to other receptors, NR2B-selective drugs might have improved therapeutic efficiency and side effect profile.
OBJECTIVES: We aimed to compare the effects of (S)-ketamine and two different types of NR2B-selective antagonists on functional brain networks in rats, in order to find common circuits, where their effects intersect, and that might explain their antidepressant action.
METHODS: The experimental design comprised four parallel groups of rats (N = 37), each receiving (S)-Ketamine, CP-101,606, Ro 25-6981 or saline. After compound injection, we acquired resting-state functional magnetic resonance imaging time series. We used graph theoretical approach to calculate brain network properties.
RESULTS: Ketamine and CP-101,606 diminished the global clustering coefficient and small-worldness index. At the nodal level, all compounds induced increased connectivity of the regions mediating reward and cognitive aspects of emotional processing, such as ventromedial prefrontal cortex, septal nuclei, and nucleus accumbens. The dorsal hippocampus and regions involved in sensory processing and aversion, such as superior and inferior colliculi, exhibited an opposite effect.
CONCLUSIONS: The effects common to ketamine and NR2B-selective compounds were localized to the same brain regions as those reported in depression, but in the opposite direction. The upregulation of the reward circuitry might partially underlie the antidepressant and anti-anhedonic effects of the antagonists and could potentially serve as a translational imaging phenotype for testing putative antidepressants, especially those targeting the NR2B receptor subtype.

Entities:  

Keywords:  Graph theory; NMDA receptor; Rat; Resting-state fMRI

Mesh:

Substances:

Year:  2018        PMID: 29305627     DOI: 10.1007/s00213-017-4823-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  4 in total

1.  NMDA receptor antagonists traxoprodil and lanicemine improve hippocampal-prefrontal coupling and reward-related networks in rats.

Authors:  Robert Becker; Natalia Gass; Lothar Kußmaul; Bernhard Schmid; Stefan Scheuerer; David Schnell; Cornelia Dorner-Ciossek; Wolfgang Weber-Fahr; Alexander Sartorius
Journal:  Psychopharmacology (Berl)       Date:  2019-07-02       Impact factor: 4.530

2.  Differences between ketamine's short-term and long-term effects on brain circuitry in depression.

Authors:  Natalia Gass; Robert Becker; Jonathan Reinwald; Alejandro Cosa-Linan; Markus Sack; Wolfgang Weber-Fahr; Barbara Vollmayr; Alexander Sartorius
Journal:  Transl Psychiatry       Date:  2019-06-28       Impact factor: 6.222

3.  Dyrk1a gene dosage in glutamatergic neurons has key effects in cognitive deficits observed in mouse models of MRD7 and Down syndrome.

Authors:  Véronique Brault; Thu Lan Nguyen; Javier Flores-Gutiérrez; Giovanni Iacono; Marie-Christine Birling; Valérie Lalanne; Hamid Meziane; Antigoni Manousopoulou; Guillaume Pavlovic; Loïc Lindner; Mohammed Selloum; Tania Sorg; Eugene Yu; Spiros D Garbis; Yann Hérault
Journal:  PLoS Genet       Date:  2021-09-29       Impact factor: 5.917

4.  Structural connectivity and subcellular changes after antidepressant doses of ketamine and Ro 25-6981 in the rat: an MRI and immuno-labeling study.

Authors:  Raquel Pascual-Antón; Arantxa Blasco-Serra; Emma Muñoz-Moreno; Fuencisla Pilar-Cuéllar; Emilio Garro-Martínez; Eva Florensa-Zanuy; Xavier López-Gil; Víctor M Campa; Guadalupe Soria; Albert Adell
Journal:  Brain Struct Funct       Date:  2021-08-07       Impact factor: 3.270

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.